Dini D, Gozza A, Silvestro S, Cavallari M, Forno G
Servizio di Rieducazione Funzionale, Istituto Nazionale per la Ricerca sul Cancro, Genova.
Minerva Chir. 1995 Apr;50(4):431-4.
Post-mastectomy lymphedema of the upper limb, that can be noticed by 10 to 20 percent of patients with breast cancer, is usually related to some risk factors: use of radiotherapy on the axilla, obesity, venous outflow obstruction, delayed wound healing or infection. The most important contributing factor to postsurgical edema is the development of lymphangitis in the upper limb. Although literature contains numerous accounts on the use of pharmacological agents for the treatment of postmastectomy lymphedema, the results are not satisfactory in term of clinical response and side effects. In the present study we investigate tolerability and feasibility of the use of suledexide in patients, submitted to mastectomy for breast cancer, with an initial lymphedema of the limb omolateral to surgery or other risk factors for the development of a clinical remarkable lymphedema. Our results show that sulodexide is a very satisfactory therapy in term of lack of side effects and good compliance.
乳腺癌患者中10%至20%会出现乳房切除术后上肢淋巴水肿,这通常与一些风险因素有关:腋窝放疗、肥胖、静脉流出道梗阻、伤口愈合延迟或感染。术后水肿最重要的促成因素是上肢淋巴管炎的发生。尽管文献中有许多关于使用药物治疗乳房切除术后淋巴水肿的报道,但在临床反应和副作用方面结果并不令人满意。在本研究中,我们调查了舒洛地昔在因乳腺癌接受乳房切除术、患侧上肢初期淋巴水肿或有发生明显临床淋巴水肿其他风险因素的患者中的耐受性和可行性。我们的结果表明,就无副作用和良好的依从性而言,舒洛地昔是一种非常令人满意的治疗方法。